These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19479954)

  • 41. Human immunodeficiency virus type 1-anchored CD40 ligand induces secretion of the chemokine interleukin-8 by human primary macrophages.
    Maurais E; Cantin R; Tremblay MJ
    Virology; 2009 Mar; 385(1):227-32. PubMed ID: 19101003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular characterization of patients with X-linked Hyper-IgM syndrome: description of two novel CD40L mutations.
    Rangel-Santos A; Wakim VL; Jacob CM; Pastorino AC; Cunha JM; Collanieri AC; Niemela JE; Grumach AS; Duarte AJ; Moraes-Vasconcelos D; Oliveira JB
    Scand J Immunol; 2009 Feb; 69(2):169-73. PubMed ID: 19170966
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.
    Ghia P; Chiorazzi N; Stamatopoulos K
    J Intern Med; 2008 Dec; 264(6):549-62. PubMed ID: 19017179
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis.
    Munroe ME
    Semin Immunol; 2009 Oct; 21(5):283-8. PubMed ID: 19539498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The structural basis of hyper IgM deficiency - CD40L mutations.
    Thusberg J; Vihinen M
    Protein Eng Des Sel; 2007 Mar; 20(3):133-41. PubMed ID: 17307885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.
    Rizvi M; Pathak D; Freedman JE; Chakrabarti S
    Trends Mol Med; 2008 Dec; 14(12):530-8. PubMed ID: 18977174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation.
    Li XL; Ménoret S; Le Mauff B; Angin M; Anegon I
    Transplantation; 2008 Jul; 86(1):10-5. PubMed ID: 18622269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulatory B cells in autoimmune diseases: how do they work?
    Lemoine S; Morva A; Youinou P; Jamin C
    Ann N Y Acad Sci; 2009 Sep; 1173():260-7. PubMed ID: 19758160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel disease-causing CD40L mutation reduces expression of CD40 ligand, but preserves CD40 binding capacity.
    Günaydin NC; Chou J; Karaca NE; Aksu G; Massaad MJ; Azarsiz E; Ertan Y; Geha RS; Kütükçüler N
    Clin Immunol; 2014 Aug; 153(2):288-91. PubMed ID: 24845792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagement.
    Ellmark P; Ohlin M; Borrebaeck CA; Furebring C
    J Mol Recognit; 2004; 17(4):316-22. PubMed ID: 15227638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene transfer of noncleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions.
    Masuta Y; Kato K; Tomihara K; Nakamura K; Sasaki K; Takahashi S; Hamada H
    J Immunother; 2007 Oct; 30(7):694-704. PubMed ID: 17893562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospect of targeting the CD40 pathway for cancer therapy.
    Vonderheide RH
    Clin Cancer Res; 2007 Feb; 13(4):1083-8. PubMed ID: 17317815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and characterization of functional CD154 (CD40 ligand) in the Pekin duck.
    Fischer KP; Gares SL; Wang D; Lorne Tyrrell D; Gutfreund KS
    Dev Comp Immunol; 2007; 31(1):61-71. PubMed ID: 16837046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD40-independent engagement of mammalian hsp70 by antigen-presenting cells.
    Binder RJ
    J Immunol; 2009 Jun; 182(11):6844-50. PubMed ID: 19454680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and functional analysis of novel variants of the human melanocortin 1 receptor found in melanoma patients.
    Pérez Oliva AB; Fernéndez LP; Detorre C; Herráiz C; Martínez-Escribano JA; Benítez J; Lozano Teruel JA; García-Borrón JC; Jiménez-Cervantes C; Ribas G
    Hum Mutat; 2009 May; 30(5):811-22. PubMed ID: 19338054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Individual and epistatic effects of genetic polymorphisms of B-cell co-stimulatory molecules on susceptibility to pemphigus foliaceus.
    Malheiros D; Petzl-Erler ML
    Genes Immun; 2009 Sep; 10(6):547-58. PubMed ID: 19421221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Solid-phase synthesis of CD40L mimetics.
    Bianco A; Fournel S; Wieckowski S; Hoebeke J; Guichard G
    Org Biomol Chem; 2006 Apr; 4(8):1461-3. PubMed ID: 16604209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.
    Wyzgol A; Müller N; Fick A; Munkel S; Grigoleit GU; Pfizenmaier K; Wajant H
    J Immunol; 2009 Aug; 183(3):1851-61. PubMed ID: 19596991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
    Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
    Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using CD40-activated B cells to efficiently identify epitopes of tumor antigens.
    Kondo E; Gryschok L; Schultze JL; von Bergwelt-Baildon MS
    J Immunother; 2009; 32(2):157-60. PubMed ID: 19238014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.